Zacks Investment Research
04 Nov 2026, 15:55 UTC · 55m ago
Impact · against what's priced in
The article provides no material catalyst for MAZE, as it merely aggregates existing analyst price targets and general sentiment. Since the stock has already climbed 22% recently, the market is already reacting to the positive outlook described.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish · 0 new · 2 priced in
The mean analyst price target for Maze Therapeutics is $62.54, representing a 93.9% potential upside from the last close of $32.25.
Priced inanalysis of consensus targets
So whatThe gap between the low target of $46.00 and the current price suggests a minimum expected gain of 42.6%.
More positive than 92% of claims this week
Analysts are showing a positive trend in earnings estimate revisions for Maze Therapeutics.
Continue reading
5 related stories
The stock's recent 22% gain suggests the market is already pricing in the positive analyst sentiment and price targets mentioned in the report.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inno timing evidence
So whatPositive revisions typically lead to upward pressure on the stock multiple ahead of the next earnings print.
More positive than 75% of claims this week
Which stocks this story touches
More positive than 94% of ticker scores this week
The stock has gained 22% recently and has a significant potential upside according to analyst price targets and earnings revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
55m ago
+2.0%
Price agrees with the score
$32.90 vs $32.25 close before publication (Nov 3) · not market-adjusted
MAZE chart →
